丁苯酞联合依达拉奉右莰醇治疗缺血性脑卒中的疗效及成本

Efficacy and Cost of Butylphthalide combined with Edaravone Dexborneol in the Treatment of Ischemic Stroke

目的探讨丁苯酞联合依达拉奉右莰醇治疗缺血性脑卒中的疗效及成本。方法通过查阅牡丹江医学院附属第二医院的医院信息系统(HIS),收集2021年1—12月所有使用丁苯酞氯化钠注射液联合依达拉奉右莰醇注射用浓溶液、依达拉奉右莰醇注射用浓溶液的缺血性脑卒中患者住院规范治疗信息,共获取945例患者。为了避免错误分类,对两组患者基线特征进行混杂控制,采用倾向评分匹配法(1∶1)匹配联合组和对照组,945例缺血性脑卒中患者最终确定丁苯酞联合依达拉奉右莰醇+常规治疗为联合组270例,依达拉奉右莰醇+常规治疗为对照组270例。比较两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、超敏C反应蛋白(hs-CRP)及临床疗效、成本、安全性。结果治疗后,两组NIHSS评分、hs-CRP水平降低,且联合组下降幅度更大,差异有统计学意义(P<0.05);联合组显效率高于对照组,差异有统计学意义(P<0.05);两组治疗有效率比较,差异无统计学意义(P>0.05);两组总药费、检查费、化验费、治疗费、直接医疗成本比较差异无统计学意义(P>0.05);两组均无明显不良反应发生。结论与单用依达拉奉右莰醇比较,丁苯酞联合依达拉奉右莰醇治疗缺血性脑卒中,显效率更高,可有效改善患者神经功能,但经济性相当。

Objective To explore the efficacy and cost of butylphthalein combined with Edaravone Dexborneol in the treatment of ischemic stroke.Methods After referring to the information system(HIS)of the Second Affiliated Hospital of Mudanjiang Medical College,all the hospitalized standard treatment information of ischemic stroke patients using sodium butylphthalide chloride injection combined with Edaravone dextrocamphorol injection concentrated solution and Edaravone dextrocamphorol injection concentrated solution from January 2021 to December 2021 were collected,and a total of 945 cases were obtained.In order to avoid misclassification,the baseline characteristics of the two groups of patients were confounding control.Propensity score matching method(1:1)was used to match the combination group and the control group.945 patients with ischemic stroke were finally determined to be butaphthalein combined with edaravone dexcamphorol plus conventional treatment,270 cases were in the combination group,and 270 cases in the control group were classified as edaravone dexcamphorol plus conventional treatment.The National Institutes of Health Stroke Scale(NIHSS)score,hypersensitive C-reactive protein(hs-CRP),clinical efficacy,cost and safety of the two groups were compared before and after treatment.Results After treatment,the NIHSS score and hs-CRP level of the two groups were decreased,and the decrease was greater in the combined group,with statistical significance(P<0.05).The efficiency of combination group was higher than that of control group,the difference was statistically significant(P<0.05).There was no significant difference in treatment effectiveness between the two groups(P>0.05).There was no significant difference in total drug cost,inspection cost,laboratory cost,treatment cost and direct medical cost between the two groups(P>0.05).No obvious adverse reactions occurred in both groups.Conclusion Compared with Edaravone dextrocamphorol alone,butylphthalein combined with Edaravone dextrocamphorol is more effective in the treatment of ischemic stroke,and can effectively improve the neurological function of patients,but the economy is similar.